Treatment for Calcium Phosphate Kidney Stone Disease

Study ID
032012-058

Cancer Related
No

Healthy Volunteers
No

Study Sites

  • UT Southwestern-Clinical Translational Research Center (CTRC)
  • UT Southwestern Ambulatory Services
  • Zale Lipshy University Hospital
  • Parkland Health & Hospital System

Contact
Sudeepa Bhattacharya
214/648-0395
sudeepa.bhattacharya@utsouthwestern.edu

Principal Investigator
Naim Maalouf, M.D.

Official Title

Pharmacological Therapy for Calcium Phosphate Urolithiasis

Brief Overview


The investigators will examine in two studies whether citric acid or potassium citrate can
reduce calcium phosphate saturation in urine of Calcium Phosphate stone formers.

Summary


We will examine in two short-term placebo-controlled cross-over metabolic studies whether
citric acid or potassium citrate can reduce calcium phosphate saturation in urine of CaP
stone formers. The first study will be conducted in hypocitraturic CaP stone formers without
hypercalciuria, and will compare the effects of potassium citrate, citric acid and placebo.

The second study will be conducted in hypercalciuric CaP stone formers on a thiazide
diuretic who require potassium supplementation, and will compare the effects of potassium
chloride alone, potassium chloride + citric acid, and potassium citrate alone.
Physicochemical assays will be applied in addition to computer-based stone risk prediction
programs to assess risk of stone recurrence.

Participant Eligibility


Inclusion Criteria:

Aim 1

- Hypocitraturic CaP stone formers

- urine citrate <320mg/d

- elevated pH as 24-hr urine pH above 6.40

- >21 years

Aim 2

- Hypercalciuric CaP stone formers

- 24hr urine calcium >250mg/d in women and >300mg/d in men prior to indapamide use

- high pH as >6.40 in the absence of urinary tract infection

- >21 years